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Background/rationale: Introducing new or testing existing drugs in an attempt to modify the progress of
osteoarthritis (OA) is of paramount importance.
Questions/purposes: This study aims to determine the effect exerted by Calcitonin on the progress of
early-stage osteoarthritic lesions.
Methods:We used 18, skeletally mature, white, female, New Zealand rabbits. OA was operatively induced
in the right knee of each animal by the complete dissection of the anterior cruciate ligament, complete
medial meniscectomy and partial dissection of the medial collateral ligament. Postoperatively, animals
were divided into two groups. Starting on the ninth postoperative day and daily thereafter, group A
animals (n ¼ 9) received 10 IU oculus dexter (o.d.) of synthetic Calcitonin IntraMuscularly (I.M.); group B
animals (n ¼ 9) received equal volume of saline o.d. Three animals from each group were sacriﬁced at 1, 2
and 3 months following treatment’s initiation. The extent and the grade of OA were assessed macro-
scopically, histologically and by radiographs, Computed Tomography (CT) and Magnetic Resonance Im-
aging (MRI)-scans. The Osteoarthritis Research Society International (OARSI) score, incorporating
histological and macroscopic information, was calculated for each knee.
Results: Osteoarthritic changes in group A animals were less severe and progressed less rapidly when
compared with those of group B animals (sham). This difference was statistically signiﬁcant in the ﬁrst
and second month (P ¼ 0.05), but not in the third month (P ¼ 0.513).
Conclusions: I.M. administration of Calcitonin seems to delay the progress of early-stage osteoarthritic
lesions induced by mechanical instability in a rabbit experimental model.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) affects nearly 27 million Americans1. The
total annual cost of OA per person living with OA is $5,7002. If these
two numbers are combined the magnitude of the importance of
treatment of OA is beginning to emerge. The pharmacological
agents that have been commonly used in order to treat patients
suffering from OA are known either as Symptom Modifying Oste-
oArthritis Drugs (SMOADs), such as pain relievers and Non-
Steroidal Anti-Inﬂammatory Drugs (NSAIDs), or Disease Modi-
fying OsteoArthritis Drugs (DMOADs) that include Chondroitin
Sulfate, Glucosamine Sulfate and Diacerein, as well as the newer
DMOADs that are under evaluation. The latest drugs, belonging toSchool, Thessaloniki, Greece.
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os).
s Research Society International. Pthe DMOADs group, that are currently developed can be broadly
divided into four categories, regarding their pathway through
which they affect progression of OA. These are: genetics, cartilage
metabolism, synovial inﬂammation and remodeling of subchondral
bone. This last group regarding the remodeling of the subchondral
bone includes Bisphosphonates, Strontium Ranelate and Calcitonin,
among others3.
The hyaline cartilage of the joints is deprived of blood vessels and
its integrity greatly depends on the status of the subchondral bone4.
If the subchondral bone could be ‘assisted’ by an anti-osteoclastic
agent, such as Calcitonin, then it is possible that the overlying
articular cartilage would be positively affected as well. Furthermore,
there is evidence (even though sometimes conﬂicting) that Calci-
tonin might interfere in a therapeutic manner with the metabolism
of cartilage and chondrocyte, especially in patients suffering from
OA5e8. Calcitonin has been used since 1984 (Food and Drug Admin-
istration (FDA) approval) in osteoporosis treatment and Paget’s dis-
ease due to its anti-osteoclastic action and its pain relieving effect9.ublished by Elsevier Ltd. All rights reserved.
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the administration of Calcitonin delays the progress of mechani-
cally induced osteoarthritic lesions in a drastic model of experi-
mentally induced OA in rabbits and to evaluate the results by
radiography, Computed Tomography (CT)-scan, Magnetic Reso-
nance Imaging (MRI)-scan, macroscopically and histologically.
Materials and method
This study was performed on eighteen skeletally mature, fe-
male, white, New Zealand rabbits. All animals were 1 year-old and
their mean weight was ﬁve kilograms (500 g). Skeletal maturity
was conﬁrmed radiographically. OA was operatively induced on all
animals1012. All operations took place under general anesthesia
(ketamine 25 mg/kg and midazolam 5 mg/kg). Following a medial
parapatellar exposure to the right knee of each animal, a complete
dissection of the cranial cruciate ligament was performed, com-
bined with a complete medial meniscectomy and a partial dissec-
tion of the medial collateral ligament. This surgical intervention
aimed to create instability, which in turnwould induce OA and also
simulate a common injury pattern of the human knee, the “O’Do-
noghue’s” or “terrible” triad of the knee. Absorbable sutures were
used for the closure of the wound. Postoperatively, all animals
received intramuscularly enroﬂoxacin (3 mg/kg/24 h) for 5 days.
Rabbits were singly housed in cages sized 0.5m 1.1m 0.5m and
had free access to rabbit pellets and water.
On the seventh postoperative day, the bandages were removed
and the animals were randomly divided into two groups of nine
rabbits each. Starting on the ninth postoperative day, the animals of
the ﬁrst group (Group A) received daily 10 I.U. of synthetic salmon
Calcitonin intramuscularly, while the ones of the second group
(Group BePlacebo) received equal volume of saline (1 ml) daily.
Three animals from each groupwere sacriﬁced at 1, 2 and 3months
following the initiation of treatment. The animalswere sacriﬁced by
receiving intramuscularly ketamine and midazolam and then
intravenously sodium thiopental. Following their sacriﬁce, the im-
aging evaluation, consisting of standard antero-posterior and lateral
radiographs, CT-scan and MRI-scan of the knees, was taking place.
The CT-scan tomographies had a thickness of 1.5 mm, while the
MRI-scan (1.5 T) ones had 2 mm thickness. The knee joint was then
exposed and by carefully removing all the soft tissues, we per-
formed the macroscopic evaluation of the articular surface of both
the femoral and the tibial condyles. Both articular surfaces were
photographed, directly perpendicularly, from a standard distance of
10 cm with a digital camera (Hewlett Packard R 607) and the pho-
tographs were edited with a photo editing software (Adobe Pho-
toshop CS2) in order to outline both the osteoarthritic lesions and
the total articular surface. Following that procedure, the two out-
lined areas were painted and projected onto the same photograph
and with the aid of the Auto Computer Aided Design 2006 (Auto-
desk) software the exact percentage of the area of the articular
surface that showed osteoarthritic lesions was calculated. This
procedure allowed the easy and accurate calculation of the exact
percentage of the area of the articular surface of the femoral or tibial
condyles that was degenerated. Finally all specimens were histo-
logically evaluated aswell after being standardized in formaldehyde
solution 10% for 48 h and demineralized in solution of 5% nitric acid
and 5% formaldehyde. Slides of 2 mm thickness were then obtained
that were processed with solutions of 10% formaldehyde, alcohol
(70, 80, 96, 96 and 100), acetone, xylene andparafﬁn. Following
this preparation, slides of 4 m thickness were obtained and were
dyedwith hematoxylin-eosin stain, while themagniﬁcation used in
the optical microscopy ranged from 20 to 400.
The Chan et al.13 grading system was used to evaluate the im-
aging techniques. This system is based on the observation of fourparameters: (1) loss or degeneration of articular cartilage, (2)
subchondral bone sclerosis, (3) osteophyte formation and (4)
appearance of subchondral cysts. Each parameter gets a grade be-
tween 0 and 3 (0 is for normal appearance and 3 is for a completely
degenerated joint). The ﬁnal grade is calculated as the sum of the
grades for every parameter in the radiographs, CT-scan and MRI-
scan. The more osteoarthritic changes appear in a joint, the
higher is the score. There were separate grades for the femoral and
the tibial articular surfaces.
The OARSI (Osteoarthritis Research Society International)
grading system14 was used for the histological assessment. This
score ranges from 0 to 6 (0 is for normal appearance and 6 is for
advanced osteoarthric changes). We preferred this grading system
because it grades both the depth of the lesions (grade) as well as
their area (stage). As a result the ﬁnal outcome of the OARSI grading
system is the result of (grade)  (stage). As ‘stage’ of the osteoar-
thritic lesions we used the exact percentage of the articular surface
that showed osteoarthritic lesions. This percentage was calculated
by the photography and computer-aided method described.
The normality of the data distribution among different groups
was tested according to the ShapiroeWilk test. All statistical tests
were two-tailed. The alpha level for all analyses was set at 0.05.
All analyses were performed with the SPSS statistical software
(Version 12, Chicago-IL). The ManneWhitney test was used to
determine the asymptomatic signiﬁcance of the differences found
in the median imaging score between the ‘Calcitonin’ and the
‘placebo’ groups.
Results
Osteoarthritic lesions (of various degrees) were found in the
knee joints of all the animals in the imaging, macroscopic and
histological evaluation (Table I). Almost all the results of the group
A animals (Calcitonin) were better than the results of the placebo
group (group B) in every method of evaluation.
The mean score regarding the imaging results (sum of all the
scores in radiographic, CT and MRI evaluation) for group A (Calci-
tonin) were 5.5 for the animals sacriﬁced in the ﬁrst month, 14.33
for the animals of the second month and 22.83 for the animals
sacriﬁced in the third month. The results for the group B animals
(Placebo) were 11.33 for the ﬁrst month,19.17 for the secondmonth
and 24.17 for the third month respectively, with higher score
meaning worse osteoarthritic ﬁndings (joint space narrowing,
osteophytes, bone cysts, subchondral sclerosis) in the imaging
evaluation (Figs 1e5).
The mean percentage of the area covered by osteoarthritic le-
sions in group Awas 14.3% for the ﬁrst month, 18.7% for the second
month and 27.7% for the third month. Group B results were: 18.1%
for the ﬁrst month, 23.3% for the second and 29.1% for the third
month respectively.
Statistical analysis (Table II) showed statistically signiﬁcant dif-
ference (favoring group A) between the imaging results of the
femoral condyles of the animals of group A and B that were sacri-
ﬁced in the ﬁrst and second month (P ¼ 0.046) and the imaging
results of the tibial condyles of the animals sacriﬁced in the second
month postoperatively (P ¼ 0.046). Statistically signiﬁcant differ-
ence also existed between the two groups in the imaging results
of the tibia in the animals that were sacriﬁced on the second
postoperative month. There was a tendency toward signiﬁcance
between the imaging results of the tibial condyles of the two
groups in the animals that were sacriﬁced in the ﬁrst postoperative
month, while no statistically signiﬁcant difference was found be-
tween the two groups in the animals sacriﬁced in the third month.
Finally there was a statistically signiﬁcant difference (P ¼ 0.05)
between the two groups (favoring group A) in the histological
Table I
Results
Specimen X-ray MRI Sclerosis
X-ray
Sclerosis
CT
Sclerosis
MRI
Osteo
X-ray
Osteo
CT
Osteo
MRI
Cyst
X-ray
Cyst
CT
Cyst
MRI
SUM Histology Lesion
%
OARSI
Group A mean
value
0,3333 0,3333 0,3333 0 0,1667 1 1 1 0,5 0,833 0 5,5 4,1667 14,3 0,5886
Group B mean
value
1 1 1 0,6667 1 1,3333 1,1667 1 1,3333 1,167 0,6667 11,33 4 18,090 0,7236
Group AA
mean value
0,6667 1 1,3333 1,6667 1,3333 1,3333 1,3333 1,3333 1,3333 1,333 1,6667 14,33 4,3333 18,687 0,8261
Group BB
mean value
2 1,667 1,5 1,3333 1 2 2 2 1,8333 2 1,8333 19,17 3,6667 25,3425 0,9292
Group AAA
mean value
2 1,667 2,1667 2 2,3333 2,3333 2 2,3333 2 2 2 22,8333 4,3333 27,7450 1,2073
Group BBB
mean value
2,3333 2,333 2,3333 2,1667 1,8333 2,1667 2,1667 2,3333 2,1667 2,3333 2 24,1667 4,3333 29,065 1,2397
X-ray: Joint space narrowing (cartilage loss) evaluated from radiographs, MRI: Joint space narrowing (cartilage loss) evaluated from MRI-scan, Sclerosis X-ray: Subchondral
sclerosis as seen on radiographs, Sclerosis CT: Subchondral sclerosis as seen on CT-scan, Sclerosis MRI: Subchondral sclerosis as seen onMRI-scan, Osteo X-ray: Osteophytes as
evaluated from radiographs, Osteo CT: Osteophytes as evaluated from CT-scan, Osteo MRI: Osteophytes as evaluated from MRI-scan, Cyst X-ray: Subchondral cysts as seen in
radiographs, Cyst CT: Subchondral cysts as seen in CT-scan, Cyst MRI: Subchondral cysts as seen in MRI-scan, SUM: Final grade according to Chan et al. grading system,
Histology: Grade regarding the depth of the osteoarthritic lesion, according to Pritzker et al.10, Lesion %: Percentage of the area of the total articular surface that has been
degenerated, OARSI: Final OARSI score according to Pritzker et al.10, A: Animal of the Calcitonin group sacriﬁced 1 month after initiation of administration of Calcitonin, AA:
Animal of the Calcitonin group sacriﬁced 2 months after initiation of administration of Calcitonin, AAA: Animal of the Calcitonin group sacriﬁced 3 months after initiation of
administration of Calcitonin, B: Animal of the Placebo group sacriﬁced 1 month after initiation of administration of placebo, BB: Animal of the Placebo group sacriﬁced 2
months after initiation of administration of placebo, BBB: Animal of the Placebo group sacriﬁced 3 months after initiation of administration of placebo.
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surface) in the animals that were sacriﬁced on the second post-
operative month. Despite the fact that the Calcitonin group had
overall better results in all the parameters, no other statistically
signiﬁcant difference was noted.
Discussion
OA is the commonest joint disorder in humans15,16. Conserva-
tive treatment, apart from auxiliary modalities such as weight loss,
change of lifestyle, exercise, use of walking aids and physio-
therapy, is mostly dependant on the use of NSAIDs, which in turn
can cause problems from the gastrointestinal and circulatory
system17,18. The newer drugs of the DMOADs group, such as
Chondroitin Sulfate, Glucosamine Sulfate and Diacerein have
controversial results, as some scientists report satisfactory
results1921, while others question their efﬁcacy22. Most of the
trials carried-out to test the efﬁcacy of these drugs are based upon
radiographic criteria22 for the evaluation of the patients’ results,
and therefore have been questioned by others as insufﬁciently
prepared and documented23. Bisphosphonates and especiallyFig. 1. a,b: Radiographs of rabbit from the placebo group that was sRisedronate has been tested as a potent DMOAD agent (targeting
the remodeling of the subchondral bone), but despite the fact that
in a Phase-II clinical trial it was shown to reduce CTX-II levels24, it
failed to show any disease modifying effect in knee OA patients in
a Phase-III clinical trial25. Recently, another drug belonging to the
same category, Strontium Ranelate, which both reduces bone
resorption and increases bone formation, has been used in a
clinical trial and has been shown to reduce the progression of
radiographic features of spinal OA in women with osteoporosis26.
It was also found to reduce the levels of urinary CTX-II biomarker
in postmenopausal women with OA27. Still, its exact role in OA is
unknown and more trials are certainly needed in order to get safer
and sounder results. Inhibitors of Catherpsin K are also potent
DMOADs, since they could potentially affect the remodeling of
both the cartilage and the subchondral bone. Nevertheless, a
clinical Phase-II study performed in OA patients was prematurely
stopped due to adverse effects3. Regarding estrogens, a recent 2-
year clinical study examining the administration of a synthetic
steroid to postmenopausal women suggested that although bone
resorption can be attenuated, its positive effects on cartilage
degradation could not be demonstrated28.acriﬁced 1 month after the initiation of placebo administration.
Fig. 2. a,b: CT-scan of placebo group rabbit sacriﬁced 1 month after initiation of administration of placebo.
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ceutical agents or “new potentials” for older drugs that will inhibit
the progress of OA with the minimum possible side-effects. Calci-
tonin has been broadly used as an anti-osteoclastic agent for
many years. Its safety has been widely proven, when used in the
usual therapeutic doses29. Its analgesic effect is also well docu-
mented30,31. There seems to be evidence suggesting a direct
chondroprotective effect of Calcitonin in addition to its well-
established effect on bone resorption 6,8,32,33. This study hypothe-
sized that articular cartilage is greatly affected by the condition of
the underlying subchondral bone, therefore e and apart from its
potential chondroprotective action e if Calcitonin can truly pre-
serve the subchondral bone architecture and vitality, the result will
be beneﬁcial to the cartilage as well.
Our study implemented a unique experimental model of
inducing OA which was proven to be highly successful, since all
animals developed OA ﬁndings. Based on our results, Calcitonin
contributed in delaying the appearance of osteoarthritic changes;
therefore its action was beneﬁcial to the articular cartilage. How-
ever, the long term beneﬁcial effect of Calcitonin on the articular
cartilage is doubted, since the results of the specimens which wereFig. 3. MRI-scan of Calcitonin group rabbit sacriﬁced 1 month after initiation of
administration of Calcitonin.obtained from group A animals in the third month were not sta-
tistically signiﬁcantly better than group B specimens.
One possible explanation for this might be the fact that the
dissection of the cranial cruciate ligament combined with medial
meniscectomy and a partial dissection of the medial collateral lig-
ament, although proven to be a highly successful model, it may
induce a signiﬁcant destabilization of the knee. This immense
instability of the joint and the resulting destruction of its cartilage
may be overwhelming and subsequently may inhibit the full
manifestation of the positive effect(s) of Calcitonin on the osteo-
arthritic cartilage. Calcitonin’s positive effect in OA is likely to be
greater in OA models less severe than that used herein. Another
possible explanation for the decrease of the positive effect of
Calcitonin in the late stages of OA in our experimental model may
be the formation of Calcitonin antibodies in rabbits after the pro-
longed use of Calcitonin, whichmay in turn inhibit its action 34,35. In
addition to the formation of antibodies, other explanations have
been also stated, such as the desensitization of Calcitonin receptors
in bone and kidneys, or the formation of Calcitonin resistant bone
cells as a cause of acquired resistance to Calcitonin due to large
amount of Calcitonin being in the circulation36.
There aremany theories regarding theway Calcitonin delays the
progression of OA. It may well be through the beneﬁcial effect
exerted on the subchondral bone, since it is not clear whether theFig. 4. Microscopic photograph (40magniﬁcation) of articular cartilage and denuded
subchondral bone in the femur of a rabbit of the placebo group.
Fig. 5. Microscopic photograph (100 magniﬁcation) of ﬁbrillation of the articular
cartilage in the femur of a rabbit of the Calcitonin group.
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tion of the articular cartilage37. Pathological changes in the sub-
chondral bone are not necessary for the initiation of OA.
Nevertheless, once they appear, they negatively affect its progres-
sion38, even though not all cartilage damage leads to OA39.
Calcitonin is also known to stimulate glucosaminoglycan syn-
thesis40 and to increase the calcium uptake41, therefore it may
directly affect the cartilage metabolism. The latter has been
observed in several ‘in vitro’ studies, since Calcitonin was found to
stimulate in the chondrocytes of the cartilage the production of
proteoglycans and collagen type-II42,43. The latter has been veriﬁed
in animal studies as well, and especially in the earlier stages of
OA5,7. Calcitonin has also been found to increase the layer of the
articular cartilage44. This action is possibly associated with the in-
crease of the polypeptide content of the cartilage due to activationTable II
Statistically signiﬁcant results
Month of sacriﬁce Group Imaging
score
Mean imaging score
and deviations
P
Femoral condyles
First Calcitonin 4 5.0 (1,7) 0.046
4
7
Placebo 10 11.33 (1,5)
11
13
Second Calcitonin 12 14.33 (2,5) 0.046
14
17
Placebo 18 19.0 (1,7)
18
21
Tibial Condyles
Second Calcitonin 12 14.33 (2,51) 0.046
14
17
Placebo 18 19.33 (1,15)
20
20
Stage (area in percentage) of osteoarthritic lesion in tibial condyles
Month of sacriﬁce Group Stage (%) Mean stage (%) and
deviations
P
Second Calcitonin 20.9 15.14 (5,88) 0.05
15.41
9.13
Placebo 31.78 28.32 (2,98)
26.585
26.62of ornithine decarboxylase, an enzyme that is important for the
production of proteins. This assumption is further supported by the
fact that Calcitonin, as Insulin and Parathyroid Hormone, increase
the multiplication of rabbit cultivated chondrocytes 45.
It is not quite clear yet, whether Calcitonin exerts an anti-
inﬂammatory action as well. It has been observed that the syno-
vitis that co-exists in OA accelerates the degeneration of articular
cartilage and the degradation of the subchondral bone and is
mainly mediated by IL-146. Calcitonin inhibits IL-1 actions47 and
therefore it suppresses synovitis as well. IL-1 activates and pro-
motes the degradation of calciﬁed collagen. Calcitonin inhibits the
release of Caþþ and therefore inhibits this action of IL-1 as well48.
Regardless of the actual mechanism of action, the beneﬁcial
effect(s) of Calcitonin have been documented in other experimental
studies as well. Our ﬁndings were in accordance with similar
studies regarding the effect exerted by Calcitonin on OA4952.
Papaioannou et al.49 in an experimental model of OAwith section of
the cranial cruciate ligament in thirty New Zealand white rabbits
and administration of Calcitonin reported that their macroscopic
and histological ﬁndings supported the therapeutic effect of
Calcitonin on OA. Behets et al.51 in their experimental study in 12
dogs with transection of the anterior cruciate ligament of the right
knee and administration of nasal spray of Calcitonin concluded that
Calcitonin reduced cartilage OA lesions and thus might be useful in
the treatment of OA in cruciate-deﬁcient joints. Manicourt et al.50
utilized 28 dogs in an experimental study to evaluate the effect of
Calcitonin in OA. Their OA model implemented the transection of
the anterior cruciate ligament (ACL). The authors stated that
treatment with Calcitonin after ACL transection helped slow down
the development of degenerative changes and therefore may have
therapeutic beneﬁts for humans who recently had a traumatic knee
joint injury. The most recent experimental study regarding Calci-
tonin and its potential use in the treatment of OAwas performed by
Nielsen et al.52 The OAmodel used in this study was bilateral partial
medial meniscectomy in rats and Calcitonin was orally adminis-
tered. The authors’ conclusionwas that orally administered salmon
Calcitonin signiﬁcantly reduced the damage in the calciﬁed carti-
lage and the subchondral bone, especially in the rabbits that had
been ovariectomized as well.
It is extremely difﬁcult to perform such a study without making
several compromises. Therefore this study has certain limitations
as well. The reader should be aware of the fact that the hereby
presented animal osteoarthritic model seems to be a rather drastic
one. As each one of the three implemented surgical procedures can
by itself induce knee OA, it is worth stressing that Calcitonin slows
down OA disease progression in a model induced by summing the
three different surgical approaches. Summing the three procedures
induces a signiﬁcant destabilization of the knee and thereby, in-
duces impressive changes in the distribution of biomechanical
forces into the joint. Accordingly, the severity and speed of onset of
OA following combination of destabilization procedures in rabbit
knee does not parallel the OA disease in humans and may limit the
relevance of the model. Furthermore, since important biome-
chanical stresses following the extensive destabilization procedure
are expected to overcome the inherent biomechanical properties of
joint components, it is unlikely any medical treatment will prevent
cartilage degradation in the experimental model reported herein.
Based on all the pre-mentioned, the reader should be aware of the
fact that this osteoarthritic model, as well as other similar osteo-
arthritic models, does not necessarily replicate all facets of the OA
disease process in humans.
It is well understood that OA needs a multidisciplinary thera-
peutic approach. Several drugs’ categories have been developed
aiming to treat patients suffering from OA. None of them however
seems to be 100% effective, especially when other well established
M.J. Kyrkos et al. / Osteoarthritis and Cartilage 21 (2013) 973e980978contributing factors (i.e., weight, mechanical axis of the limb, joint
luxation) are not taken into account as well. In this context, Calci-
tonin seems to fulﬁll many of the requested criteria for a potent anti
OA drug. Given its safety record, it seems that the early adminis-
tration of Calcitonin in humans may contribute in delaying the
progression of OA. Nevertheless, and since the expression 53 or
not 54 of Calcitonin receptor in the human cartilage and chon-
drocyte has not been clariﬁed yet, prospective clinical studies are
certainly needed in order to conﬁrm the results of this experi-
mental paper, especially when taking into account the fact that
orally administered Calcitonin as well may have a promising role in
the treatment of OA in the near future5557.
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